Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Iceland-based Decode Genetics has reported positive top-line results from its phase I multiple dose clinical trial of heart attack prevention drug DG051.
Subscribe to our email newsletter
In the study, a total of 40 healthy subjects were exposed to DG051 at doses up to 320mg per day for seven days. DG051 was well tolerated at all dose levels tested, with no serious adverse events reported, and the company said that the drug has a pharmacokinetic profile suitable for once-a-day dosing.
The company hopes to enter DG051 into phase II trials later this year. DG051 is a first-in-class, small-molecule inhibitor designed to reduce the production of the pro-inflammatory molecule leukotriene B4.
The company pinpoints key disease genes using analysis of genotypic and medical data from over 100,000 volunteers in Iceland – more than 50% of the adult population – in tandem with genealogical data linking together the entire present-day population and stretching back over 1100 years.